Modeling the Therapeutic Efficacy of p53 Restoration in Tumors  by Martins, Carla P. et al.
Modeling the Therapeutic Efficacy
of p53 Restoration in Tumors
Carla P. Martins,1 Lamorna Brown-Swigart,1 and Gerard I. Evan1,*
1Cancer Research Institute and Department of Cellular and Molecular Pharmacology, Comprehensive Cancer Center,
University of California, San Francisco, San Francisco, CA 94143, USA
*Contact: gevan@cc.ucsf.edu
DOI 10.1016/j.cell.2006.12.007SUMMARY
Although restoration of p53 function is an at-
tractive tumor-specific therapeutic strategy, it
remains unclear whether p53 loss is required
only for transition through early bottlenecks in
tumorigenesis or also formaintenance of estab-
lished tumors. To explore the efficacy of p53
reinstatement as a tumor therapy, we used a
reversibly switchable p53 knockin (KI) mouse
model that permits modulation of p53 status
from wild-type to knockout, at will. Using the
well-characterized Em-myc lymphoma model,
we show that p53 is spontaneously activated
when restored in established Em-myc lympho-
mas in vivo, triggering rapid apoptosis and con-
ferring a significant increase in survival. None-
theless, reimposition of p53 function potently
selects for emergence of p53-resistant tumors
through inactivation of p19ARF or p53. Our study
provides important insights into the nature and
timing of p53-activating signals in established
tumors and how resistance to p53 evolves,
which will aid in the optimization of p53-based
tumor therapies.
INTRODUCTION
p53 is a transcription factor that triggers growth inhibitory
and apoptotic responses to a wide range of insults, in-
cluding DNA damage, stress, and oncogene activation.
Inactivation of p53 function, or its attendant pathway, is
a common feature of human tumors that often correlates
with increased malignancy, poor patient survival, and
resistance to treatment (Munro et al., 2005; Vogelstein
et al., 2000; Vousden and Lu, 2002). Nonetheless, while
strong selection against p53 function during tumorigene-
sis underscores the critical role that the p53 pathway
plays in suppressing the emergence of incipient tumors,
it tells us nothing about when and why such selection oc-
curred during the protracted process of tumor evolution.
The widely held ‘‘Guardian of the genome’’ (Lane, 1992)Cell 1idea is that p53 suppresses tumorigenesis principally by
mediating cellular responses to DNA damage, forestalling
clonal accumulation of mutations by inducing death or ar-
rest of damaged cells. If true, then absence of p53 is likely
a transient requirement of early tumor initiation: once a tu-
mor cell has acquired its requisite ensemble of mutations,
p53 status may thenceforth be irrelevant. On the other
hand, it may be that tumors harbor persistent and obli-
gate p53-activating signals throughout their evolution, in
which case absence of p53 is a continuous requirement
for the maintenance of established tumors. The practical
difference between these two ideas is profound: rein-
statement of p53 function is an attractive tumor-specific
therapeutic strategy (Bykov et al., 2003; Vassilev, 2005),
but it will only work if tumors harbor persistent
p53-activating signals that engage growth inhibition or
death.
The p53-deficient mouse has proven invaluable in caus-
ally implicating p53 loss in spontaneous, oncogene- and
mutagen-induced tumorigenesis and in resistance to anti-
cancer drugs (Donehower et al., 1992; Harvey et al., 1993;
Kemp et al., 1994; Schmitt et al., 1999). However, such
models shed no light on when p53 inactivation is critical
for the genesis and evolution of tumors nor on the likely
impact of restoring p53 function in established tumors.
Recently we described a unique, switchable p53 knockin
(KI) mouse model (p53KI/KI) (Christophorou et al., 2005) in
which both copies of the endogenous p53 gene have
been modified to encode the 4-hydroxytamoxifen (4-
OHT) dependent p53ERTAM protein, a fusion between
p53 and a modified form of the estrogen receptor (Vater
et al., 1996). p53KI/KI mice can be reversibly and rapidly
toggled between p53 wild-type (wt) and knockout states
by, respectively, administration or withdrawal of 4-OHT
(Christophorou et al., 2005). Our previous studies have
shown that p53ERTAM is rendered functionally competent
within1–2 hr of systemic 4-OHT administration, reverting
back to a null state after30 hr unless 4-OHT is readminis-
tered. Importantly, provision of 4-OHT to either p53KI/KI
cells in vitro or tissues ofp53KI/KImice in vivo does not itself
activate p53ERTAM but rather renders p53ERTAM compe-
tent to become activated should appropriate signals arise
in such cells. Furthermore, by all tested criteria 4-OHT-
ligated p53ERTAM is functionally equivalent to wt p53
(Ringshausen et al., 2006).27, 1323–1334, December 29, 2006 ª2006 Elsevier Inc. 1323
In the well-characterized Em-myc mouse model, trans-
genic expression of the Myc oncoprotein driven from the
immunoglobulin heavy chain enhancer leads to sporadic
eruption of clonal B cell lineage lymphomas that closely re-
semble non-Hodgkin lymphoma in humans (Adams et al.,
1985; Harris et al., 1988). The sporadic incidence of such
tumors confirms their dependence upon the aleatory ac-
quisition of secondary cooperating mutations. Indeed, as
in many human and mouse cancers, the p19ARF-Mdm2-
p53 pathway is almost invariably inactivated in Em-myc
lymphomas (Eischen et al., 1999; Schmitt et al., 1999),
emphasizing the critical role of p53 in the intrinsic tumor
suppressor response to deregulated Myc, as well as that
of p19ARF as a mediator of that response (Zindy et al.,
1998). The relevance of p53 inactivation for Myc-driven
lymphomagenesis is confirmed by the greatly increased
susceptibility of heterozygous p53+/ mice to Em-myc-
induced lymphoma, 90% of which involve loss of the re-
maining p53 allele (Eischen et al., 1999; Schmitt et al.,
1999). However, none of this speaks to whether inactiva-
tion of the p53 pathway is required early versus late or
transiently versus continuously in Myc-driven lymphoma.
To ascertain the impact of restoring p53 function in tu-
mors that have sporadically lost p53 function during tumor
evolution, we crossed the Em-myc transgene into p53KI/+
mice that carry one wt copy of p53 and one that is 4-
OHT dependent. Tumors arise in such animals through
sporadic inactivation of wt p53 function, recapitulating
the sporadic loss of p53 in human tumors. However, the
remaining switchable p53ERTAM allele can be functionally
reinstated at any time, allowing us to ascertain the short-
and long-term therapeutic impact of p53 restoration on
established tumors.
RESULTS
Status of p53 and p53ERTAM Alleles in Lymphomas
Arising in Em-myc;p53KI/+ Mice
To explore the consequences of restoring p53 function in
tumors that had evolved via sporadic p53 loss, we used
a variation on the p53 heterozygous model in which
Myc-driven tumorigenesis arises following sporadic in-
activation of a single extant wt p53 allele. Lymphoma-
prone Em-myc transgenic mice (Adams et al., 1985) were
crossed into the p53KI/+ background, which has one
copy of wt p53 and one copy of the conditional, 4-OHT-
dependent p53ERTAM allele (Christophorou et al., 2005).
Incidence of spontaneous lymphomagenesis in such Em-
Myc;p53KI/+ animals in the absence of 4-OHT treatment
was then monitored. Survival of Em-myc;p53KI/+ was
greatly reduced relative to that of Em-myc;p53+/+ mice
(Em-myc) (Figure 1; p < 0.0001) and similar to that reported
for Em-myc;p53+/ mice (Schmitt et al., 1999). Thus, the
p53ERTAM allele is nonfunctional in the absence of 4-OHT.
The increased incidence of lymphomas in Em-myc;
p53+/ animals is accompanied by frequent LOH (loss-
of-heterozygosity) of the remaining wt p53 allele in tumors
(Hsu et al., 1995; Schmitt et al., 1999). We therefore as-1324 Cell 127, 1323–1334, December 29, 2006 ª2006 Elseviersessed whether the wt p53 allele is similarly lost in lympho-
mas arising in Em-Myc;p53KI/+ mice. Indeed, Southern blot
analysis confirmed that 45% of such tumors had wt p53
deletions (Figure 2A). Moreover, sequence analysis (Table
S1) revealed that 7/7 tested tumors that ostensibly retain
the p53 wt allele harbor point mutations in the DNA binding
domain consistent with functional inactivation (http://
www.umd.be:2072) (Vousden and Lu, 2002). Levels of mu-
tant p53 protein were assayed in two of this latter class of
tumors and found to be significantly elevated (Figure S1),
as is typical of inactive p53 mutants in human cancers.
To confirm directly that p53 function is absent from all
lymphomas arising in Em-Myc;p53KI/+ mice, and that func-
tion of the p53ERTAM protein encoded by the residualp53KI
allele can be restored, cells from both p53-retaining (no
Dp53) and p53-deleted (Dp53) lymphomas were ex-
planted onto feeder cells in vitro (Schmitt et al., 1999) and
24 hr later exposed to either 4-OHT, to restore p53ERTAM
function, or vehicle (ethanol). p53 activity in each of the
two groups of tumors was assayed before and 2 hr after
4-OHT treatment by Taqman analysis of diagnostic p53
target genes (Vousden and Lu, 2002). Figure 2B shows
the relative expression of cdkn1a in three independent
lymphomas representing each of the two lymphoma
groups (Dp53 and no Dp53). In the absence of 4-OHT
(0 hr 4-OHT), all tumors exhibited similar, baseline expres-
sion of cdkn1a. By contrast, restoration of p53 function
(2 hr 4-OHT) dramatically induced cdkn1a to a similar de-
gree in each tumor group. Equivalent induction was seen
for bothmdm2 and puma (Figure S2). Vehicle-treated cells
showed no significant induction of p53 target genes rela-
tive to untreated controls (data not shown). Thus, all lym-
phomas from Em-Myc;p53KI/+ mice have inactivated wt
p53 function, via deletion or mutation of the p53 wt allele
but retain a functional, switchable p53ERTAM allele. More-
over, since p53ERTAM is spontaneously active when its
function is restored, each of the lymphomas harbors con-
stitutive p53-activating signals.
Figure 1. Survival of Em-myc;p53KI/+ Mice Is Decreased
Compared to Em-myc Animals
The survival percentage of untreated Em-myc and Em-myc;p53KI/+
animals is plotted against their age.Inc.
Figure 2. Lymphomas from Em-myc;p53KI/+ Animals Are Functionally Null for p53 in the Absence of 4-OHT
(A) Southern blot analysis of lymphomas derived from Em-myc;p53KI/+ mice (Tumors) and p53KI/+ thymus (control: Ctrl). DNA was annealed with a p53
probe that recognizes both the wt (p53 wt, 5.0 kb) and the p53ERTAM (5.9 kb) alleles. Complete or partial p53 LOH is indicated (*).
(B) Taqman analysis of six independent lymphomas that either lost (Dp53: 06, 83, 53) or retained (no Dp53: 36, 29, 20) the p53 wt allele. Relative levels
of cdkn1a immediately before (0 hr) and 2 hr after 4-OHT (100 nM) treatment are depicted for each of the lymphomas analyzed. The y axis values
indicate the percent expression of cdkn1a normalized to gus.
(C) Representative quantitative data for Trypan Blue exclusion of lymphoma cells from Em-myc;p53KI/+ mice cultured in the absence (Ctrl, solid circles)
or presence of 4-OHT (open circles). 4-OHT or vehicle was added to the cultures at day 1, indicated by arrowhead. Growth curves are presented for
six independent tumors that either deleted (Dp53: 06, 47, 83) or retained (no Dp53: 26, 20, 29) the p53 wt allele.
(D) Phase contrast images from day 4 cultures of tumor cells from Em-myc (wt p53) and Em-myc;p53KI/+ mice treated with vehicle (Ctrl) or 4-OHT at day
1. Tumor cells (round white) were grown in suspension over feeder (fibroblastic) cells.To ascertain the consequences of restoring p53 function
for proliferation and survival of lymphomas, cells derived
from 14 independent tumors arising in Em-myc;p53KI/+
mice (five Dp53; nine no Dp53) were tested in a short-
term in vitro proliferation/survival assay. As before, lym-
phoma cells were plated and 24 hr later either 4-OHT or ve-
hicle added. All the lymphomas rapidly proliferated in the
absence of 4-OHT, albeit with not unexpected differences
in rate (Figure 2C; Ctrl). Furthermore, all shared a high in-
dex of viability (R80%) prior to high confluence (typically
day 3; data not shown). In contrast, 13/14 (93%) of the
tested lymphoma cells underwent massive apoptosis
upon restoration of p53 function with 4-OHT (Figure 2C;
4-OHT). Importantly, 4-OHT treatment of control Em-myc
tumor cells arising in p53+/+ mice had no effect on eitherCell 1lymphoma cell proliferation or survival, indicating that
none of the effects observed is due to 4-OHT itself
(Figure 2D).
Our data demonstrate that, similarly to the situation in
tumors arising in Em-myc;p53+/ mice (Schmitt et al.,
1999), lymphomas arising in Em-myc;p53KI/+ mice are
functionally null for p53 in the absence of 4-OHT. Impor-
tantly, in the great majority (93%) of Em-myc;p53KI/null
tumors, all components of the p53 pathway save p53,
including constitutive upstream p53-activating signals
and downstream apoptotic p53 effector pathways, remain
intact. Since we observed no consistent differences
between the two (Dp53 and no Dp53) lymphoma groups
in their sensitivities to p53 restoration, we can exclude
the possibility of dominant-negative p53 mutations in27, 1323–1334, December 29, 2006 ª2006 Elsevier Inc. 1325
those no Dp53 tumors tested in vitro. Both groups of
tumors were therefore considered appropriate for use
in subsequent analyses and are hereafter referred to as
Em-myc;p53KI/null.
Restoration of p53 Function in Em-Myc;p53KI/null
Lymphomas Delays Tumorigenesis
Our in vitro data showed that Em-myc;p53KI/null lympho-
mas retain a functional, switchable p53ERTAM allele, which
is lethal to lymphoma cells once its function is restored. We
next addressed the therapeutic impact of p53 restoration
in established lymphomas in vivo. This cannot be easily
addressed in autocthonous tumors in Em-Myc mice, since
the response of a primary tumor to treatment can be
obscured by the outgrowth of a secondary malignancy.
Fortunately, Em-Myc lymphomas can be serially trans-
planted into syngeneic mice, where they expand into tu-
mors that closely resemble their primary forebear (Harris
et al., 1988; Schmitt et al., 2000). To exploit the obvious
advantages in experimental tractability and reproducibil-
ity of this approach, we separately transplanted Em-
Myc;p53KI/null lymphoma cells derived from three indepen-
dent primary tumors (6, 29, 68) into wt recipient mice by
intravenous injection (i.v.) and allowed tumors to develop
until palpable (typically 13–20 days posttransplantation).
At this stage, animals were randomized into two groups
and injected intraperitoneally (i.p.) with either Tamoxifen
(Tam) or control vehicle (Oil) and sacrificed 6 hr later. Lym-
phomas cells were then analyzed by flow cytometry for
DNA content (Propidium iodide, PI) and viability (Annex-
inV/PI) to determine the immediate in vivo impact of p53
restoration on tumor maintenance. Representative data
from Oil- and Tam-treated lymphomas are shown in
Figure 3A. Control-treated tumors (6 hr Oil) show a DNA
profile typical of rapidly proliferating cells together with
a modest sub-G1 population, the size of which varies be-
tween different primary tumors (not shown). By contrast,
the DNA profile from Tam-treated tumors in which p53
function had been restored for 6 hr (6 hr Tam) shows signif-
icant depletion of S and G2 populations, together with a
substantial sub-G1 population indicative of loss of viability
(Figure 3A; left panels). Annexin V/PI staining of the same
cells (Figure 3A; middle panels) confirmed widespread
apoptosis in tumors from Tam-treated mice, with the per-
centage of viable cells falling to 6.5% within only 6 hr of p53
restoration (lower left quadrants). We also assayed directly
for apoptosis in tumor tissue by TUNEL staining. This con-
firmed the dramatic extent of cell death that rapidly follows
restoration of p53 function to Em-myc;p53KI/null lymphoma
cells in vivo (Figure 3A, right panels; Figure S3). Systematic
analysis of the impact of p53 restoration on lymphoma
viability at later (>6 hr) time points was confounded by fre-
quent morbidity of Tam-treated animals, most probably
due to tumor lysis syndrome (Del Toro et al., 2005). None-
theless, we can conclude that, as observed in vitro, p53 is
spontaneously active in vivo upon functional restoration in
Em-myc;p53KI/null lymphomas, triggering rapid and wide-
spread tumor cell apoptosis.1326 Cell 127, 1323–1334, December 29, 2006 ª2006 ElsevierThe robust tumor suppressive effect we observe in vivo
upon reinstatement of p53 function in established Em-
myc;p53KI/null lymphomas suggests that p53 restoration
should have a profound therapeutic impact on long-term
survival of affected animals. To test this directly, we again
transplanted Em-myc;p53KI/null primary lymphomas into wt
recipients and randomly assigned them into control and
Tam-treatment groups (see scheme in Figure 3B). To ac-
commodate likely variability in responses between differ-
ent primary lymphomas, we independently tested four
Em-Myc;p53KI/null primary lymphomas (Dp53: 6, 68; no
Dp53: 26, 29). To decrease the mortality from catastrophic
tumor lysis, p53 function was restored 10 days posttrans-
plantation, at which stage lymphomas are not yet palpa-
ble. Daily treatments (Tam or Oil) were then maintained
for a total of 7 days. Essentially identical responses were
obtained with each of the four primary tumors tested, al-
lowing us to combine the data obtained from all trans-
planted mice into a single survival curve (Figure 3C). Con-
trol mice succumb to lethal tumors between days 14 and
25 after transplantation, with a mean survival of 18.6 days.
By contrast, Tam-treated mice die of lymphomas between
days 23 and 40 posttransplantation, a 28 day mean
survival. Thus, 7 day in vivo restoration of p53 in Em-
myc;p53KI/null lymphomas has a significant therapeutic
impact (p < 0.0001), markedly delaying tumor onset and
conferring a 50% (9.4 days) increase in mean survival.
Transient Restoration of p53 Function In Vivo
Potently Selects for p53 Resistance in Lymphomas
The recurrence of lymphomas in Tam-treated mice indi-
cates that, despite the dramatic proapoptotic impact of
p53 restoration, sufficient tumor cells escape to regener-
ate a tumor. Escape of tumor cells could arise either
through chance or due to the presence of a constitutively
p53-resistant subpopulation, perhaps refractory tumor
stem cells or preexisting p53-resistant clones. To distin-
guish between these possibilities, we assayed the sensitiv-
ity of the recurring, secondary tumors to p53 restoration.
Established secondary lymphomas harvested both from
control and Tam-treated mice (hereafter termed Post-Oil
and Post-Tam tumors, respectively) were cultured in vitro
in the presence or absence of 4-OHT. To accommodate
any intertumor variation, we assayed the growth and viabil-
ity of 10 Post-Oil and 16 Post-Tam lymphomas, derived
from all four of the primary Em-myc;p53KI/null lymphomas
used in our in vivo study. Representative data is shown in
Figure 4. Similarly to the primary tumors from which they
were derived (Figure 2C), all Post-Oil tumors were rapidly
killed upon exposure to 4-OHT (Figures 4A and 4B;
Post-Oil lymphoma). By contrast, all 16 Post-Tam tumors
continued to survive and proliferate in the presence of
4-OHT (Figures 4A and 4B; Post-Tam lymphomas), each
growing at a rate at least that of its vehicle-treated Post-
Oil lymphomas counterpart. Of note, we observed some
variation in resistance of Post-Tam tumors to 4-OHT
amongst the tumors: whereas some Post-Tam lympho-
mas were completely refractory to 4-OHT (Figure 4A; rightInc.
Figure 3. p53 Restoration in Em-myc;
p53KI/null Lymphomas Prolongs Host
Survival
(A) Representative data from Em-myc;p53KI/null
lymphomas treated (i.p.) with Tam or carrier
(Oil) and harvested 6 hr later. Flow cytometric
analysis for DNA content (PI; left panels) and
Annexin/PI (middle panels) staining of the
same control and Tam-treated tumor cells is
shown. Note that DNA content and Annexin/
PI are assessed in fixed and fresh cells, respec-
tively. TUNEL staining (brown) of lymphoma tis-
sue (lymph nodes) is presented (right panels).
Scale bar = 50 mm.
(B) Schematic representation of long-term sur-
vival study. Em-myc;p53KI/null primary tumors
(4-OHT responsive in vitro) were transplanted
into wt mice, which were then treated daily for
7 days with Tam or vehicle (Oil), starting at
day 10 after transplantation. Assessment of
the therapeutic effect of p53 restoration in lym-
phoma-bearing animals was based on tumor
survival and response of recurring lymphomas
to a second round of treatment (in vitro).
(C) The survival percentage of control (Oil) and
Tam-treated mice is plotted over time after
transplantation.panels), others showed a slightly decreased propagation
rate in its presence—most probably due to decreased
viability (Figure 4A; middle panels). We can nonetheless
conclude that transient exposure to p53 function efficiently
selects for outgrowth of 4-OHT-resistant Em-myc;p53KI/null
lymphoma clones.
Em-myc;p53KI/null Post-Tam tumors could in principle
acquire resistance to 4-OHT by one of several mecha-
nisms. First, p53ERTAM itself might be inactivated. Sec-
ond, the pathway linking Myc with p53 might be severed,
most plausibly through loss/inactivation of p19ARF. Third,
critical, nonredundant downstream p53 apoptotic/arrest
effector pathways might become corrupted. Fourth, it is
formally possible that tumor cells uptake of 4-OHT could
be compromised by multidrug resistance. To discriminate
between these possibilities, we first assessed by immuno-
blotting the status of the Myc/p19ARF/p53 axis in Post-Oil
and Post-Tam secondary lymphomas derived from all four
primary tumors used in our study. As shown in Figure 5A,Celllevels of Myc were comparable in all tumors analyzed, re-
gardless of treatment, and consistent with a continuous
requirement for Myc in lymphoma maintenance. Further-
more, all Post-Oil (O) lymphomas expressed high levels
of p19ARF as well as detectable levels of p53ERTAM pro-
tein. By contrast, Post-Tam lymphomas exhibited one of
two distinct mechanisms of resistance to p53 restoration.
In one group of Post-Tam tumors (derived from primary
lymphomas 6 and 47), p19ARF protein was absent, while
p53ERTAM remained detectable. The majority of these
tumors showed complete (5/8) or partial (2/8) deletion of
the p19ARF alleles (Figure 5B), and in all cases, ARF
mRNA expression was also lost (Figure 5C and not
shown). In the second group (derived from primary lym-
phomas 26 and 29), p19ARF levels remained high but
p53ERTAM protein was absent. Of note, this latter group
corresponded to the lymphomas that showed complete
refractoriness to 4-OHT restoration in the short-term sur-
vival studies, whereas the p19ARF-deficient tumors often127, 1323–1334, December 29, 2006 ª2006 Elsevier Inc. 1327
Figure 4. p53 Restoration In Vivo Selects
for Tumors Resistant to 4-OHT
(A) Post-Tam and Post-Oil tumors were cul-
tured in the absence (Ctrl) or presence of 4-
OHT. The proliferative rate (upper panels, rep-
resentative data) and viability (lower panels) of
tumor cells was determined by Trypan Blue ex-
clusion. 4-OHT or vehicle was added to the cul-
tures at day 1, indicated by arrowhead. The
secondary (2ary) lymphomas shown were de-
rived from Em-myc;p53KI/null primary tumors 6
(left and middle panels) and 29 (right panels).
Error bars show the standard deviation be-
tween three independent tumors.
(B) Phase contrast images from day 4 cultures
of tumor 6 derived 2ary lymphomas. Tumor cells
(round white) were grown in suspension over
feeder (fibroblastic) cells.retained some sensitivity (Figure 4A; right and middle
panels respectively). Southern blot analysis confirmed
that the p53ERTAM allele had, in fact, been deleted in this
second group (Figure 5D). Interestingly, all Post-Tam
secondary tumors that originate from a common primary
Em-myc;p53KI/null lymphoma evolve 4-OHT resistance by
the same route—one class losing p19ARF and the other
p53ERTAM (Figures 5B and 5D and data not shown).
Thus, some preexisting constraint dictates the route by
which resistance evolves.
The above data illustrate three important features of the
selective pressure that p53 restoration imposes on Em-
myc-induced lymphomas. First, even short-term restora-
tion of p53 function in established tumors imposes power-
ful selection for inactivation of the p53 pathway. Second,
while it is formally possible that the p53-resistant lym-
phoma variants could have evolved de novo after p53
was deactivated at the end of treatment, the efficiency
and rapidity with which resistant disease appears
suggests that a significant reservoir of p53-resistant cells
preexists prior to imposition of selection. Third, the
comparable likelihoods with which p19 ARF and p53ERTAM
are lost indicate that counter-selection targets the whole
p19 ARF -p53 pathway rather than favouring p53 preferen-
tially. This is intriguing, given that p19ARF loss incapaci-
tates only one of multiple p53-activating pathways that
plausibly exist in an established tumor cell.1328 Cell 127, 1323–1334, December 29, 2006 ª2006 ElsevierAcquired Resistance to p53 Restoration Can Be
Bypassed In Vitro
Our data indicate that inactivation of p19ARF is a frequent
mechanism by which established lymphomas acquire re-
sistance to the therapeutic impact of p53 functional resto-
ration. However, while inactivation of p19ARF uncouples
p53 from the constitutively activating oncogenic signal
generated by Myc, it leaves p53 function intact and, poten-
tially, accessible for therapeutic activation by other signals
such as DNA damage (Kamijo et al., 1997; Stott et al.,
1998). We therefore tested whether p53 can still be acti-
vated to therapeutic effect in p19ARF-deficient Post-Tam
lymphomas. Post-Oil and Post-Tam pairs derived from
primary lymphomas 6, 47, 68 (all of which evolve p53 resis-
tance through p19ARF loss), and 29 (that becomes resistant
through loss of p53ERTAM) were treated with either 4-OHT
or vehicle, irradiated 1 hr later, and cell viability measured
4 hr after irradiation by Annexin/PI flow cytometry. As ex-
pected, mere restoration of p53 function by addition of
4-OHT proved sufficient to induce widespread cell death
in Post-Oil lymphoma cells (Figure 6A; lower left panel,
viable cells < 2%) but not in the Post-Tam secondary
variants (Figure 6A, second left panel; Table S2). Exposure
of the same cells to g-radiation without p53 restoration
had a more muted, and variable, impact on the viability
of Post-Oil and Post-Tam tumors (viable cells: 12%–
56% and 17%–66%, respectively; Table S2). However, theInc.
Figure 5. Tumor Resistance to p53 Res-
toration Arises through Inactivation of
the p19ARF-p53ERTAM Axis
(A) Protein lysates from recurrent secondary
tumors (2ary) derived from four (6, 26, 29, 47) in-
dependent Em-myc;p53KI/null primary (1ary) lym-
phomas were probed for Myc, p53, p19ARF and
b-actin (loading control) expression by immu-
noblotting. Representative vehicle-(O) and
Tam-treated transplants are shown.
(B) Southern blot analysis of Post-Oil and Post-
Tam tumors derived from primary lymphoma 6
(1ary). An exon1b probe was hybridized with tu-
mor DNA to assess the integrity of the p19ARF
locus. wt lymph nodes and ARF/ MEFs
were used as controls (upper panel). The p53
wt and p53ERTAM loci (lower panel) were ana-
lyzed as in Figure 2A. The upper (p19ARF) and
lower (p53) panels show the same Post-Oil
and Post-Tam lymphomas.
(C) Taqman analysis of ARF expression in pri-
mary (1ary) tumor 6 and its Post-Tam derivative
tumors A, B, C, and D shown in (B). The y axis
indicates the percent expression of ARF nor-
malized to gus. Error bars show the standard
deviation between three independent mea-
surements.
(D) Southern blot analysis of Post-Oil and Post-
Tam tumors derived from primary lymphoma
29. The p53 wt and p53ERTAM loci were ana-
lyzed as in Figure 2A.combination of p53 restoration and irradiation efficiently
triggered apoptosis in Post-Tam p19ARF-deficient tumors
(third column, lower panel 4-OHT+ g-IR: viable cells %
3%). By contrast, Post-Tam tumors lacking p53ERTAM
were completely resistant to this combined treatment
(right column, lower panel and Table S2).
We next asked whether the discrete Myc-p19ARF and
DNA damage p53-activating signals can together cooper-
ate to potentiate the activation of p53 in Em-myc;p53KI/null
lymphomas. To do this, we assayed induction of p53 tar-
get genes following p53 restoration and/or g-irradiation in
both the p19ARF-proficient (Post-Oil) and p19ARF-deficient
(Post-Tam) secondary lymphomas. The proapoptotic p53
target gene puma (Figure 6B; left panel) was significantly
induced (8–11-fold) in Post-Oil tumors upon 4-OHT treat-
ment, presumably due to persistent p53 activation via the
Myc-p19ARF axis. By contrast, radiation alone induced
puma to a significantly lesser degree, presumably via
p53-independent DNA-damage pathways. Importantly,
combination of p53 functional restoration and irradiation
synergized to enhance dramatically puma induction. Nei-
ther p53 restoration nor irradiation alone appreciably in-
duced puma in p19ARF-deficient Post-Tam lymphomas.
However, puma was significantly induced, although to
only 50% of the level induced in p19ARF-proficient tu-
mors, when p53 restoration and g-irradiation were com-
bined. This is consistent with our FACS data showing
that significant apoptosis in p19ARF-deficient Post-Tam
tumors occurs only in cells cotreated with 4-OHT and irra-Cell 12diation (Figure 6A). Similar synergy was evident in the
induction of p53 target genes cdkn1a and mdm2
(Figure 6B; right panels). Taken together, we can conclude
the following three points. First, in the absence of p19ARF,
p53ERTAM remains competent to induce apoptosis when
activated by DNA damage; hence, apoptotic effector
pathways downstream of p53 remain intact. Second,
p19ARF is required for the spontaneous activation of p53
in established Em-myc lymphoma cells, since p19ARF null
cells harbor no measurable p53-activating signals. Third,
the p19ARF and DNA damage pathways exhibit significant
p53-activating synergy within the tumor cell population
when coactivated.
Combining p53 Restoration with Exogenous p53
Activation Increases the Therapeutic Impact
of p53 in Lymphomas
Our in vitro data show that acquisition of resistance to p53
restoration through loss of the endogenous p19ARF path-
way still leaves resistant cells vulnerable to p53 activation
by exogenous DNA damage. Furthermore, the distinct but
cooperative nature of the Myc-p19ARF and exogenous
DNA damage p53-activating pathways raises the possibil-
ity that coactivation of both might offer a significantly en-
hanced therapeutic effect over either alone. To test this,
wt mice were transplanted with lymphoma cells from pri-
mary tumor 6 and, 10 days later, treated as previously
with either Tam or Oil for 7 days. Half of the mice in each
cohort in addition received a single dose of g-radiation7, 1323–1334, December 29, 2006 ª2006 Elsevier Inc. 1329
Figure 6. DNA Damage Restores p53
Response in p19ARF-Deficient Post-Tam
Em-myc; p53KI/null Lymphomas
(A) Flow analysis of AnnexinV/PI staining of
Post-Oil and Post-Tam lymphomas, treated in
vitro with 4-OHT or carrier (Ctrl) and exposed
1 hr later to 4 Gy of g-irradiation (g-IR). Tumor
cells were collected 5 hr after Ctrl/4-OHT treat-
ment. Viable cells occupy the lower left quad-
rant of each panel, while early apoptotic and
late apoptotic/dead cells appear in the lower
right and upper right quadrant, respectively.
The tumors analyzed were derived from pri-
mary lymphoma 6 (Post-Oil and Post-Tam-no
p19ARF) and 29 (Post-Tam-no p53ERTAM).
(B) Post-Oil and Post-Tam lymphomas derived
from primary tumor 6 were treated as above,
collected 4 hr after Ctrl/4-OHT treatment (3 hr
after irradiation, g-IR), and analyzed by Taq-
man for puma, mdm2, and cdkn1 expression.
Representative data of three Post-Oil and
Post-Tam lymphomas is shown. The y axis
indicates the percent expression of puma,
mdm2, or cdkn1 normalized to gus. These
samples were also probed by immunoblotting
for the expression of p19ARF and b-actin (load-
ing control).2 hr after the first injection of Tam (or Oil). As shown in Fig-
ure 7, radiation treatment (IR) alone offered only a small
(11%) and statistically insignificant (p = 0.844) increase
in mean survival compared with Oil-treated animals
(mean survival: 20 versus 18 days for IR and Oil, respec-
tively). Tam treatment extended mean survival to 26
days (equivalent to a 44% [8 day] increase) relative to Oil
treatment. However, when g-radiation and Tam treatment
were combined, 50% of the mice survived more than 31.5
days, which corresponds to a significant (p = 0.002) in-
crease in mean survival of 30% over Tam treatment alone
and a 75% extension (13.5 days) in mean survival relative
to control (Oil-treated) animals. Thus, combining p53
restoration with exogenous DNA damage significantly
enhances the therapeutic impact of p53 restoration in
established tumors, providing direct in vivo evidence of
synergy between the intrinsic p19ARF-p53 tumor suppres-
sor and the exogenous DNA-damage-p53 pathways.
DISCUSSION
The frequent inactivation of p53 in human tumors (Vogel-
stein et al., 2000; Vousden and Lu, 2002) suggests that re-
storing p53 function in tumor cells might be an attractive1330 Cell 127, 1323–1334, December 29, 2006 ª2006 Elsevierand tumor cell-specific strategy for treating cancers. How-
ever, it is axiomatic that p53 restoration will only work as
a cancer therapy if p53-activating signals persist in estab-
lished tumor cells. Whereas p53 inactivation in cancers
unequivocally demonstrates the strong selection against
p53 pathway activity at some point during tumor evolu-
tion, it does not tell us when such selection occurs, or
why. Using a genetic model of p53 restoration we now es-
tablish, for the first time, that p53-activating signals are
persistent features of an established tumor, what the
nature of such signals is, and whether they are sufficient,
either alone or in combination with other p53-activating
signals, to achieve a therapeutic effect.
Our study shows that untreated Em-myc;p53KI/+ mice
resemble Em-myc;p53+/ animals (Schmitt et al., 1999),
developing lymphoma at similar accelerated rates relative
to Em-myc mice. All lymphomas arising in Em-myc;p53KI/+
mice were functionally null for p53, due to sporadic dele-
tion or mutation of the wt p53 copy. This recapitulates
the sporadic loss of p53 in lymphomas arising in Em-myc;
p53+/ mice, where p53 LOH frequency ranges from 55%
(Hsu et al., 1995) to 94% (Schmitt et al., 1999). Interest-
ingly, and in contrast to some human tumors and germline
mutations of Li Fraumeni syndrome carriers (Royds andInc.
Iacopetta, 2006; Sigal and Rotter, 2000), we found no ev-
idence for dominant-negative p53 mutations in Em-myc;
p53KI/null lymphomas, perhaps reflecting the fact that in
the absence of 4-OHT there is selective pressure against
only a single p53 allele in Em-myc;p53KI/+ tumorigenesis.
Indeed, in none of the primary tumors did we observe
loss of the p53ERTAM allele, confirming the functional
inactivity of p53ERTAM in the absence of 4-OHT (Christo-
phorou et al., 2005).
In vitro restoration of p53 function to Em-myc;p53KI/null
lymphoma cells triggered dramatic and rapid induction
of p53 target genes, as well as apoptosis, confirming the
functional competence of the residual p53ERTAM allele in
the presence of 4-OHT. Importantly, since 4-OHT does
not itself activate p53ERTAM but, instead, merely restores
its functionality, such spontaneous p53ERTAM activity
suggests that cultured Em-myc tumor cells harbor consti-
tutive, persistent p53-activating signals. However, in vitro
culture is known to expose cells to a variety of p53-activat-
ing insults (Sherr and DePinho, 2000). Therefore, to con-
firm that persistent p53-activating signals are inherent to
established Em-myc;p53KI/null lymphoma cells and not in
vitro artifacts, we also assessed the effects of restoring
p53 function in vivo following (i.v.) transplantation of pri-
mary tumors into multiple wt recipients. Restoration of
p53 function in tumors triggered rapid and widespread ap-
optosis within 6 hr of Tam treatment, confirming the pres-
ence in Em-myc;p53KI/null lymphoma cells in vivo of both
constitutive upstream p53-activating signals and func-
tional downstream effectors. Indeed, induction of tumor
cell death was so potent that many animals with large
tumors became moribund following Tam treatment (data
not shown), consistent with the recognized phenomenon
of tumor lysis syndrome (Del Toro et al., 2005). Thus, our
Figure 7. Extrinsic DNA-Damage Signals Improve the Thera-
peutic Response of Em-Myc;p53KI/null Lymphomas to p53
Restoration
Wild-type mice were transplanted with untreated cells from primary tu-
mor 6 and treated for 7 days with Tam or vehicle (Oil) as in Figure 3C.
Half the mice from each group also received a single dose of g-irradi-
ation (4 Gy; IR) 2 hr after the first Tam/Oil treatment (day 10, arrow). The
survival percentage for the four groups of mice is plotted against time
after transplantation.Cell 1data demonstrate for the first time that p53 inactivity is,
indeed, essential for maintenance of established tumors.
Transient (7 day) restoration of p53 in Em-myc;p53KI/null
lymphomas also exerted a significant therapeutic impact
on survival, leading to a 50% increase in mean survival
over that of controls. Importantly, this therapeutic effect
was not limited to particular tumors but observed with
similar efficacy in each of four distinct Em-myc;p53KI/null
primary lymphomas (increase in mean survival: 44%–
57%). p53 restoration also extended the disease-free
phase, delaying overt tumor onset from 14 to 23 days
posttransplantation. Thus, p53 restoration in lymphomas
is a credible tumor-specific therapy.
Nonetheless, despite the delay afforded by p53 restora-
tion all treated animals eventually relapsed. Since we only
restored p53 transiently, one possibility was that tumors
recur because p53 fails to kill a small, innately apoptosis-
resistant ‘‘tumor stem cell’’ population that regenerates
the original (p53 sensitive) tumor when p53 function is
switched back off. Such a p53-resistant population was
recently identified in bone marrow progenitors (Wu et al.,
2005). However, tumor stem cell regeneration seems an
untenable explanation given that the entirety of cells within
each of the recurring, Post-Tam-treated tumors exhibits
p53 resistance. Indeed, we show that resistance to p53
restoration arises through somatic inactivation of either
p53ERTAM or p19ARF, most commonly through gene dele-
tion. Thus, the resurgent secondary tumors are likely the
product of a pre-existing, exapted, and p53-resistant sub-
population within the original tumor that expands under the
selective pressure imposed by p53 restoration. Intrigu-
ingly, all 2nd generation Tam-resistant tumors arising
from a common primary tumor evolved 4-OHT resistance
via the same route (i.e., all inactivatep19ARFor all inactivate
p53ERTAM). This supports the notion that rare clones har-
boring specific resistance-conferring mutations pre-exist
prior to transplantation and p53 selection. Moreover, the
evolutionary route adopted for p53 resistance appears
constrained by the initial mechanism via which p53 func-
tion is inactivated. Thus, all (4/4) primary lymphomas that
delete the wt p53 gene gave rise to 4-OHT-resistant sec-
ondary tumors that lose p19ARF expression. Conversely,
2/2 primary lymphomas with p53 wt allele mutations
spawned second-generation 4-OHT-resistant tumors
that lose p53ERTAM. It will be doubtless informative to
ascertain the evolutionary constraints at play.
Recent data show that the tumor suppressive function
of p53 in incipient neoplasms is triggered by p19ARF
rather than DNA damage (Christophorou et al., 2006;
Efeyan et al., 2006). Here we asked whether p19ARF is
also the principal conduit of p53 activation in established
tumors. The comparable frequencies of p53ERTAM and
p19ARF inactivation in p53-resistant tumors indicates
that selective pressure operates against the whole Myc-
p19ARF-p53ERTAM axis rather than preferentially against
p53, implying that loss of p53 confers no significant
oncogenic advantage over loss of p19ARF. Indeed, loss
of p19ARF or p53 seems to confer a broadly equivalent27, 1323–1334, December 29, 2006 ª2006 Elsevier Inc. 1331
selective advantage for tumor growth, since the sur-
vival of mice bearing p53ERTAM or p19ARF-deficient lym-
phomas is very similar (not shown). This is surprising
given that established Em-myc;p53 null lymphomas might
be expected to harbor a variety of p19ARF-independent
p53-activating signals, such as DNA damage. Indeed,
Em-myc;p53 null lymphomas are typically aneuploid due
to underlying chromosomal instability (Schmitt et al.,
1999). Moreover, Myc overexpression in vitro induces re-
active oxygen species, which generates DNA double-
strand breaks (Vafa et al., 2002), while Myc overexpres-
sion in the mouse epidermis in vivo can activate p53 via
an ATM-mediated DNA-damage response (Pusapati
et al., 2006). Finally, persistent DNA damage is reported
to be a frequent feature in human cancers from their ear-
liest stages, possibly due to deregulated DNA replication
(Bartkova et al., 2005; Gorgoulis et al., 2005). For all these
reasons, loss of p53 might have been expected to confer
significant tumorigenic advantage over p19ARF loss. One
possibility is that additional mutations might be responsi-
ble for the inability of p19ARF-deficient Em-myc;p53KI/null
lymphomas to undergo p53-dependent apoptosis. How-
ever, this seems unlikely given that both the p53ERTAM
present in p19ARF-deficient Em-myc;p53KI/null lympho-
mas, and its downstream effector pathways, all remain
functionally competent and activatable by exogenous
DNA damage, triggering widespread apoptosis. Alterna-
tively, DNA damage may be infrequent and sporadic, trig-
gering only an ephemeral p53-activating signal that rap-
idly attenuates after the immediate genomic injury has
been resolved (Christophorou et al., 2006). Whatever
the explanation, our data indicate that p19ARF is the
only persistent determinant of p53 triggering in estab-
lished Em-myc lymphoma.
Nonetheless, the slight growth inhibitory effect of p53
restoration on p19ARF-deficient tumor cells (Figure 4A) in-
dicates that, although weak, p19ARF-independent, p53-
activating signals remain present in Em-myc;p53KI/null lym-
phoma cells. This raises the possibility that p19ARF might
cooperate with such signals to activate p53. Indeed, we
show that the presence of p19ARF significantly potentiates
activation of p53 by DNA damage in lymphoma cells, con-
sistent with the notion that Myc-p19ARF and DNA-damage
signaling pathways act as independent conduits to p53
activation that can be combined to augment p53 activity
within the tumor population. However, whether such co-
operation arises through potentiation of p53 activity within
each individual cell or by each pathway co-opting p53 in
discrete tumor cell populations remains unclear.
The p53-activating synergy between p19ARF and DNA-
damage signals offers an accommodation for apparent
contradictions in the role p19ARF plays in the p53-medi-
ated DNA-damage response. While several investigators
find no requirement for p19ARF in p53-mediated DNA-
damage responses (Christophorou et al., 2006; Kamijo
et al., 1997; Stott et al., 1998), others do. For example,
ARF/ mouse embryonic fibroblasts (MEFs) show re-
duced p53-dependent responses to ionizing radiation1332 Cell 127, 1323–1334, December 29, 2006 ª2006 Elsevier I(Khan et al., 2000), ATM and p19ARF collaborate to induce
p53 Ser15 phosphorylation in cell lines (Li et al., 2004), and
p19ARF deficiency can reverse the premature senescence
of ATM/ MEFs (Kamijo et al., 1999). Our guess is that
while p19ARF does not directly mediate DNA-damage
activation of p53, in cells where p19ARF is constitutively
expressed, such as tumor cells and cells cultured in vitro,
it elevates basal p53 activity, so lowering the threshold
for its activation by DNA damage.
In turn, the cooperation between the Myc-p19ARF and
DNA-damage axes in p53 activation suggests that the
therapeutic efficacy of harnessing endogenous, onco-
gene-induced p19ARF signals in tumors might be en-
hanced by coexposing tumors to exogenous DNA dam-
age. Indeed, the combination of p53 restoration with
irradiation significantly delayed lymphomagenesis com-
pared with either treatment alone. Moreover, the combina-
tion was synergistic rather than merely additive. Although
such combined treatment still failed to prevent ultimate re-
lapse, it offered a 75% increase in mean survival com-
pared with that of control-treated mice. Thus, the synergy
between p53 restoration and DNA damage extends not
only to the extent of p53 activation but also to the thera-
peutic outcome of such activation. Of note, lymphomas
recurring after combined treatment all lost p19ARF but
retained expression of p53ERTAM and, consequently, re-
tained sensitivity to the subsequent combination of p53
restoration and DNA damage (Figures S4A and S4B).
These recurring tumors may thus arise from cells that es-
caped the initial DNA-damage insult, most probably due to
an insufficient dose of irradiation. This suggests that the
therapeutic outcome of p53 restoration may be improved
by coexposure to more aggressive levels of irradiation or
systemic treatment with a chemotherapeutic. By demon-
strating how restoration of p53 to p53 null tumors can en-
hance the therapeutic response to irradiation in tumors,
our data also underscore the pivotal role that p53 function-
ality plays in response to cancer therapies (Brown and
Attardi, 2005; Gudkov and Komarova, 2003).
In summary, our data strongly support the principle that
p53 restoration has potent therapeutic potential against
established tumors. However, it is not just the status of
p53 itself that determines therapeutic efficacy of p53 res-
toration but also the status of p53-activating signals that
pre-exist, or can be induced, in the tumor cells. Moreover,
while the subsequent evolution of p53-resistant clones re-
mains a major stumbling block to long-term eradication of
disease, by enlisting both endogenous and exogenous
p53-activating pathways in tumor cells, it is possible to
maximize both the potency and extent of p53 activation
within the tumor cell population and so optimize the ther-
apeutic benefit that p53 restoration affords.
EXPERIMENTAL PROCEDURES
Mice and Lymphoma Cultures
Animals were kept under SPF conditions and maintained under ap-
proved UCSF IACUC protocols. Em-myc mice (Adams et al., 1985)nc.
(C57BL/6, Jackson Laboratories) were crossbred to p53KI/+ (Christo-
phorou et al., 2005) (C57BL/6-129/Ola) to obtain Em-myc and Em-myc;
p53KI/+ progeny. Mice were sacrificed when tumor diameterR 1.5 cm
or terminally ill (survival curves) or when indicated. Statistical analysis
of survival was performed with the Kaplan-Meier log-rank test. Lym-
phomas were collected and fixed (histopathology), frozen (Southern
analysis) or processed to single-cell suspensions, aliquoted, and fro-
zen. Lymphomas were cultured as described (Schmitt et al., 1999).
Twenty-four hours after plating, 100 nM 4-OHT or vehicle (ethanol)
was added to the cultures, which were followed for 3 additional
days. Cell number and viability was assessed daily by Trypan Blue
exclusion. Where appropriate, cells were irradiated (4 Gy) 1 hr after
4-OHT/ethanol treatment. Mice and cells were irradiated using
a Mark 1-68 137Cesium source (0.637 Gy/min).
Lymphoma Transplantation and In Vivo Treatment
Prior to transplantation, independent aliquots of all primary lympho-
mas used were tested in vitro to confirm response to 4-OHT treatment.
For transplants, lymphoma cells were thawed immediately before
use, washed, counted, and injected intravenously (106 cells/mouse
in 200 ml phosphate-buffered saline [PBS]) into multiple genetically
matched wt mice (immunosuppressed with 4 Gy 3–6 hr prior to trans-
plantation). For short-term p53 restoration studies and survival curves,
4–6 and 8–14 recipients were used per primary tumor, respectively. For
practicality and economy in in vivo studies, we substituted 4-OHT
with Tam, which is rapidly and efficiently converted to 4-OHT by the
liver and has identical pharmacological efficacy in vivo to 4-OHT, as
an activator of ERTAM (unpublished data). Tam (1 mg/100 ml of peanut
oil/mouse) or carrier was administered once, when tumors were palpa-
ble (0.5 cm diameter: short-term studies) or daily for 7 days, from day
10 posttransplantation.
Southern Analysis
For Southern analysis, 10 mg of genomic DNA/sample were digested
with EcoRV (p53) or AflII (p19ARF), separated in a 0.7% agarose gel,
transferred to a nylon membrane, and hybridized with 32[P] labeled
probes (Rediprime II RPN1633, Amersham).
Cell Cycle and Viability
For cell-cycle analysis, 1 3 106 freshly isolated lymphoma cells were
ethanol-fixed, incubated with propidium iodide (PI) (50 mg/ml PI, 0.5
mg/ml RNase A in PBS) for 30 min at room temperature, and analyzed.
For viability studies, 13 106 cells were washed in PBS, resuspended in
Ca/HEPES buffer (10 mM HEPES, pH 7.4; 140 mM NaCl; 2.5 mM
CaCl2) and incubated with Annexin V (FITC: 556419 BD-Pharmingen)
for 30 min. PI was added prior to analysis. Samples were analyzed us-
ing a Becton-Dickinson FACSCalibur flow cytometer. TUNEL staining
of formalin-fixed, paraffin-embedded tissue sections was performed
using the ApopTag Peroxidase in situ system (Chemicon International).
Immunoblotting
Lymphoma cells were analyzed for protein expression essentially as
described (Martins and Berns, 2002). Protein lysates (50 mg) were
run in 4%–20% gradient gels (Invitrogen) and blotted on to PVDF mem-
branes (Immobilon-P). The antibodies used were pan-Myc (Moore
et al., 1987), anti-p53 (CM5, Vector), anti-p19ARF (C3, Novus), and
anti-b-Actin (AC-15, Sigma).
Taqman Analysis
Total RNA was isolated with RNeasy kit (Qiagen) and DNase treated
(Invitrogen 18068-015) prior to reverse transcription (iScript, BioRad).
Taqman analysis was performed as previously described (Christo-
phorou et al., 2005). All data were normalized to gus expression.Cell 1Supplemental Data
Supplemental data include four figures and two tables and can be
found with this article online at http://www.cell.com/cgi/content/full/
127/7/1323/DC1/.
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